Skip to content
Head to head

Revolution Medicines vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: RVMD · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

RVMD +133.2%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
RVMDVRTX
Snapshot
Sector--Biotechnology
Last price161.20515.02
Change today+1.11%-1.08%
1-year return+130.7%+22.0%
Market cap$34.87B$130.58B
52-week range71.15 – 224.31412.27 – 568.67
Valuation
P/E (TTM)-17.6633.14
P/E percentile, own 5-yr range15th99th
P/B14.526.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-5.9515.32
Net profit (TTM)$-1.29B$3.88B
Revenue (TTM)$197.56M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin-853.0%33.1%
Net margin-946.8%30.7%
Free cash flow (TTM)$-1.44B$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership99.8%96.8%
Insider activity (12mo)12 buy / 38 sell28 buy / 22 sell
Short interest (% of float)6.1%1.9%
Analyst consensus96% buy / 4% hold (23)95% buy / 5% hold (21)
Analyst price target$268 (+66%)$624 (+21%)
StockVane view
StockVane Quant RatingD (98)C (68)
Company
Employees8836,400
Founded20041989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.